tetrahydro-11-deoxycortisol has been researched along with Cancer of Pituitary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Lange, WE; Doorenbos, H; Pratt, JJ; Sluiter, WJ | 1 |
| de Lange, WE; Dullaart, RP; Hew, JM; Molenaar, WM; Sluiter, WJ; Tjeerdsma, G | 1 |
2 other study(ies) available for tetrahydro-11-deoxycortisol and Cancer of Pituitary
| Article | Year |
|---|---|
Plasma 11-deoxycortisol, androstenedione, testosterone and ACTH in comparison with the urinary excretion of tetrahydro-11-deoxycortisol as indices of the pituitary-adrenal response to oral metyrapone.
Topics: 17-Hydroxycorticosteroids; Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Androstenedione; Cortodoxone; Female; Humans; Hydrocortisone; Male; Metyrapone; Middle Aged; Pituitary Neoplasms; Pituitary-Adrenal System; Testosterone; Tetrahydrocortisol; Time Factors | 1980 |
Hyperprolactinaemia is associated with a higher prevalence of pituitary-adrenal dysfunction in non-functioning pituitary macroadenoma.
Topics: Adenoma; Adult; Aged; Corticotropin-Releasing Hormone; Cortodoxone; Female; Humans; Hydrocortisone; Hyperprolactinemia; Hypoglycemia; Male; Middle Aged; Pituitary Neoplasms; Pituitary-Adrenal System | 1996 |